Page 120 - 《中国药房》2025年20期

Cent，2024，4（1）：47-53. line treatment for patients over the age of 65 or 75 with
[ 2 ] BOURREAU C，TREPS L，FAURE S，et al. Therapeutic metastatic non-small cell lung cancer（NSCLC）[J]. J Che‐
strategies for non-small cell lung cancer：experimental mother，2024，36（8）：675-681.
models and emerging biomarkers to monitor drug effica‐ [15] 杨艳青，陈伟，马璟婷，等. PD-1/PD-L1抑制剂一线治疗
cies[J]. Pharmacol Ther，2023，242：108347. 晚期非鳞状非小细胞肺癌有效性及安全性的网状Meta
[ 3 ] 中华医学会肿瘤学分会 . 中华医学会肺癌临床诊疗指 分析[J/OL]. 中国胸心血管外科临床杂志，2024：1-10.
南：2024 版[J]. 中华医学杂志，2024，104（34）：3175- [2025-04-16].https：//link.cnki.net/urlid/51.1492.R.20240416.
3213. 1153.010. DOI：10.7507/1007-4848.202312068.
[ 4 ] HUANG Q，KEMNADE J，CORNWELL L，et al. Non- [16] ZHANG X W，WU M，CHEN J，et al. Comparative efficacy
small cell lung cancer in the era of immunotherapy[J]. of immune checkpoint inhibitors combined with chemo‐
Semin Oncol，2022，49（3/4）：337-343. therapy in patients with advanced driver-gene negative
[ 5 ] LU S，WANG J，YU Y，et al. Tislelizumab plus chemo‐ non-small cell lung cancer：a systematic review and
therapy as first-line treatment for locally advanced or network meta-analysis[J]. Heliyon，2024，10（10）：e30809.
metastatic nonsquamous NSCLC（RATIONALE 304）：a [17] FU W F，XU M M，SHI X Y，et al. Comparison of the pro‐
randomized phase 3 trial[J]. J Thorac Oncol，2021，16（9）： files of first-line PD-1/PD-L1 inhibitors for advanced
1512-1522. NSCLC lacking driver gene mutations：a systematic review
[ 6 ] YANG Y P，WANG Z H，FANG J，et al. Efficacy and and Bayesian network meta-analysis[J]. Ther Adv Chronic
safety of sintilimab plus pemetrexed and platinum as first- Dis，2023，14：20406223231189224.
line treatment for locally advanced or metastatic nonsqua‐ [18] ZHAO M Y，SHAO T H，REN Y N，et al. Identifying opti‐
mal PD-1/PD-L1 inhibitors in first-line treatment of patients
mous NSCLC：a randomized，double-blind，phase 3 study
with advanced squamous non-small cell lung cancer in
（oncology program by InnovENT anti-PD-1-11）[J]. J
China：updated systematic review and network meta-
Thorac Oncol，2020，15（10）：1636-1646.
[ 7 ] HERBST R S，GIACCONE G，DE MARINIS F，et al. analysis[J]. Front Pharmacol，2022，13：910656.
[19] HUO G W，LIU W J，KANG S，et al. Toripalimab plus
Atezolizumab for first-line treatment of PD-L1-selected
chemotherapy vs. chemotherapy in patients with advanced
patients with NSCLC[J]. N Engl J Med，2020，383（14）：
non-small-cell lung cancer：a cost-effectiveness analysis
1328-1339.
[J]. Front Pharmacol，2023，14：1131219.
[ 8 ] MOK T S K，WU Y L，KUDABA I，et al. Pembrolizumab
[20] WANG H，LONG Y C，XU Y，et al. Economic evaluation
versus chemotherapy for previously untreated，PD-L1-
of toripalimab combined with chemotherapy in the treat‐
expressing，locally advanced or metastatic non-small-cell
ment of non-small cell lung cancer[J]. Front Public
lung cancer（KEYNOTE-042）：a randomised，open-label，
Health，2023，11：1137255.
controlled，phase 3 trial[J]. Lancet，2019，393（10183）：
[21] ZHANG H X，LI L F，FENG L，et al. Biomarkers-based
1819-1830.
cost-effectiveness of toripalimab plus chemotherapy for
[ 9 ] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会
patients with treatment-naive advanced non-small cell
（CSCO）非小细胞肺癌诊疗指南：2024[M]. 北京：人民卫
lung cancer[J]. Adv Ther，2023，40（11）：4945-4956.
生出版社，2024：134-174. [22] ZHOU K X，SHU P，ZHENG H R，et al. Cost-
[10] 唐惠林，门鹏，翟所迪. 药物快速卫生技术评估方法及应 effectiveness analysis of toripalimab plus chemotherapy
用[J]. 临床药物治疗杂志，2016，14（2）：1-4.
as the first-line treatment in patients with advanced non-
[11] 嵇承栋，朱琳懿，万悦竹，等. 国际卫生技术评估机构协
small cell lung cancer（NSCLC）without EGFR or ALK
作网卫生技术评估报告清单解读[J]. 中国循证医学杂
driver mutations from the Chinese perspective[J]. Front
志，2016，16（3）：369-372.
Pharmacol，2023，14：1133085
[12] SHEA B J，REEVES B C，WELLS G，et al. AMSTAR 2：a [23] ZHANG M D，XU K，LIN Y T，et al. Cost-effectiveness
critical appraisal tool for systematic reviews that include analysis of toripalimab plus chemotherapy versus chemo‐
randomised or non-randomised studies of healthcare inter‐ therapy alone for advanced non-small cell lung cancer in
ventions，or both[J]. BMJ，2017，358：j4008. China[J]. Front Immunol，2023，14：1169752.
[13] HUSEREAU D，DRUMMOND M，AUGUSTOVSKI F， [24] ZHENG Z W，ZHU G F，CAO X Q，et al. A cost-
et al. Consolidated health economic evaluation reporting effectiveness analysis of first-line toripalimab plus chemo‐
standards 2022（CHEERS 2022）statement：updated re- therapy in advanced nonsquamous non-small cell lung
porting guidance for health economic evaluations[J]. cancer in China[J]. Expert Rev Clin Pharmacol，2023，16
BMJ，2022，376：e067975. （3）：267-273.
[14] LANDRE T，CHOUAÏD C，SADAOUI N，et al. Clinical （收稿日期：2025-05-06 修回日期：2025-09-14）
benefit of anti-PD-1/PD-L1 plus chemotherapy in first- （编辑：陈 宏）

· 2598 · China Pharmacy 2025 Vol. 36 No. 20 中国药房 2025年第36卷第20期